• BECOME A MEMBER
  • MEMBER LOG IN
  • FIND A CLINIC
  • ru
    • en
    • es
    • fr
    • da
    • it
    • cs
    • pl
    • nl
    • no
    • sv
    • pt
    • de
  • EHDN and
    Enroll-HD 2024
  • ABOUT HD
  • ABOUT EHDN
  • NEWS & EVENTS
  • HD Patients and Families
    • HD Patients and Families Home
    • Living with HD
    • Finding Clinics and Support
    • HD Research
  • HD Clinicians and Researchers
    • HD Clinicians and Researchers Home
    • Previous & Ongoing Research
    • Publications
    • EHDN Working Groups
    • Rater training and certification
    • Seed Fund Applications
    • Data-Mining Applications
    • Fellowship programme
    • Grant Management & Collaborations
  • Clinical Trial Sponsors
    • Clinical Trial Sponsors Home
    • Feasibility Assessment
    • Protocol Advice
    • Operational Support
    • Recruitment
    • Clinical Rater Training
    • HD Clinical Trial Site Certification Scheme
  • About Huntington's Disease
  • About EHDN
    • EHDN Structure
    • EHDN Working Groups
    • Grant Management & Collaborations
    • HD Clinics
    • Previous & Ongoing Research
    • Resources and Services
  • News & Events
  • REGISTRY LOGIN
  • MEMBER LOG IN
  • Find a Clinic
Skip to content
European Huntington's Disease Network
  • HD Patients and Families
    • Patients & Families Home
    • Living with HD
    • Finding Clinics and Support
    • HD Research
  • HD Clinicians and Researchers
    • Clinicians & Researchers Home
    • HD Science Think Tank
    • EHDN Working Groups
    • Fellowship programme
    • Seed Fund Applications
    • Grant management & Collaborations
    • Data-Mining Applications
    • Rater training and certification
    • Research & Publications
    • Guidelines
  • Clinical Trial Sponsors
    • Clinical Trial Sponsors Home
    • Protocol Advice
    • Feasibility Assessment
    • Operational Support
    • Recruitment
    • Clinical Rater Training
    • Site Certification Scheme

Рубрика: Uncategorized

March 23rd: HUNTINGTON’s Gratitude Day 2023

Posted on Март 23, 2023 by Lisanne Muetze

On March 23rd, 1993, scientists announced the discovery of the gene causing Huntington’s Disease (HD). […]

Read More…

EHDN Newsletter – 48th edition

Posted on Март 1, 2023 Edited Март 1, 2023 by Lisanne Muetze

The EHDN newsletter (archive) aims to communicate the network’s activities and other developments of interest in the field of Huntington’s disease to the lay community, healthcare professionals and scientists. It appears three times a year (March 1, July 1, Nov 1). To receive EHDN news going forward, please subscribe to the EHDN news at the […]

Read More…

HDYO International Young Adults Congress

Posted on Февраль 24, 2023 Edited Февраль 24, 2023 by Lisanne Muetze

March 17-19, 2023 in Glasgow, Scotland […]

Read More…

CHDI’s 18th Annual Huntington’s Disease Therapeutics Conference

Posted on Февраль 20, 2023 Edited Февраль 20, 2023 by Lisanne Muetze

… to be held April 24 through 27, 2023, in Dubrovnik, Croatia. The conference program will cover all aspects of HD drug development, including the latest advances in understanding HD pathophysiology, novel HD therapeutic approaches, current and emerging biomarkers, and updates on ongoing clinical trials. […]

Read More…

28 February, 2023 IS RARE DISEASE DAY

Posted on Февраль 20, 2023 Edited Февраль 20, 2023 by Lisanne Muetze

Raising awareness and generating change for the 300 million people worldwide living with a rare disease, their families and carers. […]

Read More…

PTC Therapeutics PIVOT-HD study endorsed* by EHDN

Posted on Ноябрь 16, 2022 by Lisanne Muetze

Study aims and goal: The primary goal of this study is to evaluate the safety and pharmacodynamic effects of PTC518 and placebo in participants with HD. No. of study participants and sites: This phase IIa study aims to recruit participants from sites in Australia, France, Germany, Netherlands, the UK and the US. For further information […]

Read More…

FELLOWSHIP NOW OPEN FOR APPLICATIONS

Posted on Ноябрь 14, 2022 by Lisanne Muetze

Fellowship Exchange Programme in Huntington’s Disease is now open for applications. Are you a young/recently qualified clinician interested in learning more about HD? […]

Read More…

EHDN Newsletter – 47th edition

Posted on Ноябрь 3, 2022 Edited Ноябрь 3, 2022 by Katrin Barth

The EHDN newsletter (archive) aims to communicate the network’s activities and other developments of interest in the field of Huntington’s disease to the lay community, healthcare professionals and scientists. It appears three times a year (March 1, July 1, Nov 1). To receive EHDN news going forward, please subscribe to the EHDN news at the […]

Read More…

Sage Therapeutics DIMENSION-HD study endorsed* by EHDN

Posted on Октябрь 27, 2022 by Lisanne Muetze

Study aims and goal: The primary purpose of this study is to evaluate the effect of SAGE-718 on cognitive performance and functioning in participants with HD. No. of study participants and sites: This phase II study aims to recruit participants from approximately 50 sites in Australia, Europe and North America. For further information see the […]

Read More…

Sage Therapeutics SURVEYOR-HD study endorsed* by EHDN

Posted on Октябрь 27, 2022 by Lisanne Muetze

Study aims and goal: The primary purpose of this study is to assess the magnitude of the baseline difference between participants with early Huntington’s Disease (HD) and healthy participants (HP) with respect to measures of cognitive performance and the effect of SAGE-718 on cognitive performance and functioning in participants with HD. No. of study participants […]

Read More…

Навигация по записям

Предыдущие записи
Следующие записи

Subscribe to
EHDN news

* Denotes required field
  • © EHDN 2016
  • Terms of Use
  • Privacy Policy
  • Contact EHDN
  • University of Ulm
LinkedIn